Paeoniflorin protects against nonalcoholic fatty liver disease induced by a high-fat diet in mice

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 7, 2015, Pages 1005-1011

  Zhang, Lijing ^a   Yang, Bin ^a   Yu, Baoping ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Gluconeogenesis; Hyperlipidemia; Inflammation; Nonalcoholic fatty liver disease; Paeoniflorin

Indexed keywords

ABC TRANSPORTER A1; CARNITINE PALMITOYLTRANSFERASE I; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER X RECEPTOR ALPHA; PAEONIFLORIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); GLUCOSE BLOOD LEVEL; GLUCOSIDE; PROTECTIVE AGENT; TERPENE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID METABOLISM; DRUG MECHANISM; DYSLIPIDEMIA; FATTY ACID OXIDATION; FATTY LIVER; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; GLUCONEOGENESIS; HEART PROTECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIVER PROTECTION; MALE; MOUSE; MOUSE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANALYSIS; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGAN SIZE; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; GLUCOSIDES; LIPID METABOLISM; LIVER; MALE; MICE, INBRED C57BL; MONOTERPENES; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; ORGAN SIZE; PROTECTIVE AGENTS; TRANSCRIPTOME;

EID: 84936857611     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00892     Document Type: Article

References (30)

1. Hassan K, Bhalla V, Ezz El Regal M, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J. Gastroenterol., 20, 12082-12101 (2014).
2. Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl. Res., 164, 312-322 (2014).
3. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol, 6, 263-273 (2014).
4. Corey KE, Kaplan LM. Obesity and liver disease: the epidemic of the twenty-first century. Clin. Liver Dis., 18, 1-18 (2014).
5. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ, 349, g4596 (2014).
6. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology, 147, 754-764 (2014).
7. Wang QS, Gao T, Cui YL, Gao LN, Jiang HL. Comparative studies of paeoniflorin and albiflorin from Paeonia lactiflora on antiinflammatory activities. Pharm. Biol., 52, 1189-1195 (2014).
8. Yu HY, Liu MG, Liu DN, Shang GW, Wang Y, Qi C, Zhang KP, Song ZJ, Chen J. Antinociceptive effects of systemic paeoniflorin on bee venom-induced various 'phenotypes' of nociception and hypersensitivity. Pharmacol. Biochem. Behav., 88, 131-140 (2007).
9. Juan YC, Tsai WJ, Lin YL, Wang GJ, Cheng JJ, Yang HY, Hsu CY, Liu HK. The novel anti-hyperglycemic effect of Paeoniae radix via the transcriptional suppression of phosphoenopyruvate carboxykinase (PEPCK). Phytomedicine, 17, 626-634 (2010).
10. Xiao L, Wang YZ, Liu J, Luo XT, Ye Y, Zhu XZ. Effects of paeoniflorin on the cerebral infarction, behavioral and cognitive impairments at the chronic stage of transient middle cerebral artery occlusion in rats. Life Sci., 78, 413-420 (2005).
11. Tan S, Li M, Ding X, Fan S, Guo L, Gu M, Zhang Y, Feng L, Jiang D, Li Y, Xi W, Huang C, Zhou Z. Effects of Fortunella margarita fruit extract on metabolic disorders in high-fat diet-induced obese C57BL/6 mice. PLoS ONE, 9, e93510 (2014).
12. Cong WN, Tao RY, Tian JY, Liu GT, Ye F. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci., 82, 983-990 (2008).
13. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J. Gastroenterol., 20, 14205-14218 (2014).
14. Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD. Int. J. Mol. Sci., 14, 21240-21257 (2013).
15. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep., 2, 282-286 (2001).
16. Terauchi Y. PPARgamma and metabolic syndrome. Rinsho Byori, 55, 447-451 (2007).
17. Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab., 23, 65-72 (2012).
18. Tang XL, Deng LB, Lin JR, Zhang WL, Liu SM, Wei Y, Mei PM, Wang Y, Liang SD. Sterol regulatory element binding protein 1 and its target gene networks. Yi Chuan, 35, 607-615 (2013).
19. Harwood HJ Jr. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome. Curr. Opin. Investig. Drugs, 5, 283-289 (2004).
20. Brownsey RW, Boone AN, Elliott JE, Kulpa JE, Lee WM. Regulation of acetyl-CoA carboxylase. Biochem. Soc. Trans., 34, 223-227 (2006).
21. Wolfgang MJ, Lane MD. Hypothalamic malonyl-CoA and CPT1c in the treatment of obesity. FEBS J., 278, 552-558 (2011).
22. Mansour M. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Prog. Mol. Biol. Transl. Sci., 121, 217-266 (2014).
23. Chen L, Yang G. PPARs integrate the mammalian clock and energy metabolism. PPAR Res., 2014, 653017 (2014).
24. Haines BE, Wiest O, Stauffacher CV. The increasingly complex mechanism of HMG-CoA reductase. Acc. Chem. Res., 46, 2416-2426 (2013).
25. Kidani Y, Bensinger SJ. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol. Rev., 249, 72-83 (2012).
26. Afonso Mda S, Castilho G, Lavrador MS, Passarelli M, Nakandakare ER, Lottenberg SA, Lottenberg AM. The impact of dietary fatty acids on macrophage cholesterol homeostasis. J. Nutr. Biochem., 25, 95-103 (2014).
27. Xiao L, Wang J, Jiang M, Xie W, Zhai Y. The emerging role of constitutive androstane receptor and its cross talk with liver X receptors and peroxisome proliferator-activated receptor A in lipid metabolism. Vitam. Horm., 91, 243-258 (2013).
28. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol., 56, 952-964 (2012).
29. Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z. Gastroenterol., 45, 63-70 (2007).
30. Samad F, Badeanlou L, Shah C, Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv. Exp. Med. Biol., 721, 67-86 (2011).